Delhi, India — Authorities in Delhi have dismantled a large-scale illegal drug operation, revealing one of the most extensive counterfeit antacid factory bust Delhi schemes this year. The Delhi Police busts fake ENO manufacturing racket involved the seizure of thousands of ENO antacid counterfeits seized Delhi, highlighting the growing public health threat posed by unregulated pharmaceutical operations.
Illegal Drug Manufacturing Unit in Delhi, India
The operation, conducted by the Delhi Police Crime Branch, uncovered an illegal drug manufacturing unit Delhi India producing fake antacid products for local and regional distribution. Investigators seized counterfeit medicine packaging equipment, empty capsules, and branded labeling materials. This counterfeit antacid factory bust Delhi marks a significant enforcement action against organized pharmaceutical fraud.
Ghaziabad Fake Drug Factory Raid and Regional Links
Authorities traced supply chains to Ghaziabad, executing a Ghaziabad fake drug factory raid that revealed further production of counterfeit ENO and other medications. The investigation highlights counterfeit drug crime Delhi police Crime Branch initiatives targeting cross-district networks exploiting regulatory gaps.
Scale of the Seizure: Fake Medicine Manufacturing India 2025
Officials report the bust resulted in thousands of fake medicines seized, including tablets, sachets, and capsules, making this one of the largest fake medicine manufacturing India 2025 cases. The operation illustrates persistent challenges in curbing illegal pharmaceutical distribution India.
Health Risks and Consumer Safety Concerns
Experts warn the proliferation of counterfeit drugs poses serious health risks. Health risk counterfeit medicines India is heightened by untested formulations and substandard packaging. Authorities emphasize timely raids to prevent these products from entering pharmacies and retail chains.
Fake Consumer Goods Pharmaceutical Racket India
Investigators found links between counterfeit ENO production and other fake consumer goods pharmaceutical racket India operations, showing how illicit networks diversify product lines to increase profits. Vigilant monitoring of imports, local production, and distribution channels is essential.
Legal Action and Enforcement
Delhi Police officials confirmed arrests in the counterfeit pharmaceuticals legal action India case. Detainees face charges under the Drugs and Cosmetics Act for producing, distributing, and selling unauthorized pharmaceutical products. These arrests reinforce law enforcement’s commitment to combating counterfeit drug operations and protecting public health.
Technological Solutions to Prevent Counterfeit Drugs
While enforcement actions remain critical, blockchain-based pharmaceutical traceability platforms, such as Synchrypt, can provide real-time oversight across the supply chain. By recording shipment data, verification checkpoints, and transfer histories, Synchrypt can help prevent diversion, strengthen regulatory monitoring, and reduce the risk of counterfeit drugs in India reaching consumers.
References:
DrugsControl.org — Delhi Police Busts Fake ENO Manufacturing Racket